1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

J&J/Janssen gain 1st US approval in MDR-TB with Sirturo

 
• By Donna Young

The US FDA and Janssen, a subsidiary of Johnson & Johnson, waited until the last day of 2012 to reveal regulators had granted an accelerated approval three days earlier to Sirturo (bedaquiline) as the first drug in the US to treat pulmonary multi-drug resistant tuberculosis (MDR-TB).

The US FDA and Janssen, a subsidiary of Johnson & Johnson, waited until the last day of 2012 to reveal regulators had granted an accelerated approval three days earlier to Sirturo (bedaquiline) as the first drug in the US to treat pulmonary multi-drug resistant tuberculosis (MDR-TB).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapeutic Category

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.